Literature DB >> 11434508

Heterogeneity in hand veins responses to acetylcholine is not associated with polymorphisms in the G-protein beta3-subunit (C825T) and endothelial nitric oxide synthase (G894T) genes but with serum low density lipoprotein cholesterol.

M Grossmann1, D Dobrev, W Siffert, W Kirch.   

Abstract

Vascular responses to acetylcholine (ACh) are notoriously variable, the reason for this phenomenon is unknown. We tested the hypothesis that the variability in venous response to acetylcholine may be associated with two recently identified genetic polymorphisms for proteins involved in the signal transduction pathway, i.e. the G-protein beta3-subunit (GNB3) and endothelial nitric oxide synthase (eNOS). The dorsal hand vein technique was used in 37 healthy subjects. Hand veins were preconstricted with the alpha1-adrenoceptor agonist phenylephrine and the venodilator response to local ACh infusion was measured with and without comedication of acetylsalicylic acid or co-infusion of N(G)-monomethyl-L-arginine (L-NMMA). In addition, all subjects received routine laboratory tests and 26 of them were genotyped for the C825T polymorphism of the GNB3 gene and for the G894T polymorphism of the eNOS gene. A striking variability in venous response to ACh was found with dilation observed in the low ACh concentration range and reduced dilation or even constriction at high concentrations. ACh-induced venodilation was mediated by muscarinic receptors and abolished in the presence of both acetylsalicylic acid and L-NMMA suggesting dependence on endothelium. We did not find any association of the variability in ACh response with GNB3 or eNOS allele status. On the other hand, a significant positive correlation between ACh responsiveness and low density lipoprotein-cholesterol status was detected. Two recently discovered gene polymorphisms are not responsible for the profound heterogeneity in venodilator response to ACh. Surprisingly, this variability appears to relate to the lipid status of the subjects. The exact nature of this new finding requires further study.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11434508     DOI: 10.1097/00008571-200106000-00005

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  4 in total

1.  Endothelial venodilator response in carriers of genetic polymorphisms involved in NO synthesis and degradation.

Authors:  Ruth Fricker; Christiane Hesse; Johanna Weiss; Yorki Tayrouz; Michael M Hoffmann; Kristina Unnebrink; Ulrich Mansmann; Walter E Haefeli
Journal:  Br J Clin Pharmacol       Date:  2004-08       Impact factor: 4.335

2.  Statin treatment in hypercholesterolemic men does not attenuate angiotensin II-induced venoconstriction.

Authors:  Christoph Schindler; Kristina Guenther; Cosima Hermann; Carlos M Ferrario; Christoph Schroeder; Sven Haufe; Jens Jordan; Wilhelm Kirch
Journal:  PLoS One       Date:  2014-09-29       Impact factor: 3.240

3.  Bradykinin or acetylcholine as vasodilators to test endothelial venous function in healthy subjects.

Authors:  Eneida R Rabelo; Luis E Rohde; Beatriz D Schaan; Marcelo C Rubira; Karen B Ruschel; Rodrigo D M Plentz; Fernanda M Consolim-Colombo; Maria Cláudia Irigoyen; Heitor Moreno Junior
Journal:  Clinics (Sao Paulo)       Date:  2008-10       Impact factor: 2.365

4.  Metabolic and haemodynamic effects of oral glucose loading in young healthy men carrying the 825T-allele of the G protein beta3 subunit.

Authors:  Jens Nürnberger; Sandra Dammer; Thomas Philipp; Rene R Wenzel; Rafael F Schäfers
Journal:  Cardiovasc Diabetol       Date:  2003-06-25       Impact factor: 9.951

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.